Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines

AIDS Research and Human Retroviruses

Volumn 13, Issue 17, 1997, Pages 1471-1485

  Coëffier, Eliane ^a   Excler, Jean Louis ^b   Kieny, Marie Paule ^c   Meignier, Bernard ^b   Moste, Catherine ^b   Tartaglia, James ^d   Pialoux, Gilles ^a   Salmon Céron, Dominique ^e   Leclerc, Claude ^a  

^a INSTITUT PASTEUR   (France)

^b Pasteur Merieux Connaught   (France)

^c TRANSGENE S A   (France)

^d Virogenetics Corporation   (United States)

^e Hôpital de l'Institut Pasteur ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GUINEA PIG; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; MACACA; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0030810044     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.1471     Document Type: Article

References (43)

1. Rusche JR, Javaherian K, McDanal C, Petro J, Lynn DL, Grimaila R, Langlois A, Gallo RC, Arthur LO, Fischinger PJ, Bolognesi DP, Putney SD, and Matthews TJ: Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci USA 1988;85:3198-3202.
2. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD, and Matthews TJ: Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA 1989;86:6768-6772.
3. Lasky LA, Nakamura G, Smith DH, Fennie C, Shimasaki C, Patzer E, Berman P, Gregory T, and Capon DJ: Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 1987;50: 975-985.
4. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, and Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67: 6642-6647.
5. Muster T, Guinea R, Trkola A, Purtscher M, Klima A, Steindl F, Palese P, and Katinger H: Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 1994;68:4031-4034.
6. Conley AJ, Kessler JAI, Boots LJ, Tung JS, Arnold BA, Keller PM, Shaw AR, and Emini EA: Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci USA 1994;91:3348-3352.
7. Moore JP and Nara PL: The role of the V3 loop of gp120 in HIV infection. AIDS 1991;5:S21-S33.
8. Goudsmit J, Boucher CA, Meloen RH, Epstein LG, Smit L, van der Hoek L, and Bakker M: Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition. AIDS 1988;2:157-164.
9. Goudsmit J, Debouck C, Meloen RH, Smit L, Bakker M, Asher DM, Wolff AV, Gibbs CJJ, and Gajdusek DC: Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci USA 1988;85: 4478-4482.
10. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, Putney SD, Matsushita S, Cobb KE, Jett CM, Eichberg JW, and Murthy KK: Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (London) 1992;355:728-730.
11. Berman PW, Groopman JE, Gregory T, Clapham PR, Weiss RA, Ferriani R, Riddle L, Shimasaki C, Lucas C, Lasky LA, and Eichberg JW: HIV-1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proc Natl Acad Sci USA 1988;85:5200-5204.
12. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hershberg RD, Cobb EK, and Eichberg JW: Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature (London) 1990;345:622-625.
13. Bruck C, Thiriart C, Fabry L, Francotte M, Pala P, Van Opstal O, Culp J, Rosenberg M, De Wilde M, Heidt P, and Heeney J: HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine 1994;12: 1141-1148.
14. Girard M, Kieny MP, Pinter A, Barré-Sinoussi F, Nara P, Kolbe H, Kusumi K, Chaput A, Reinhart T, Muchmore E, Ronco J, Kaczorek M, Gomard E, Gluckman J-C, and Fultz PN: Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 1991;88: 542-546.
15. Fultz PN, Nara P, Barré-Sinoussi F, Chaput A, Greenberg ML, Muchmore E, Kieny MP, and Girard M: Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 1992;256:1687-1690.
16. Deng HK, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Dimarzio P, Marmon S, Sutton RE, Hill CM, DAvis CB, Peiper SC, Schall TJ, Littman DR, and Landau NR: Identification of a major co-receptor for primary isolates of HIV-1. Nature (London) 1996;381:661-666.
17. Feng Y, Broder CC, Kennedy PE, and Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
18. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, and Moser B: The lymphocyte chemoattractant SDF-1 is a ligand for lestr/fusin and blocks HIV-1 entry. Nature (London) 1996;382:829-833.
19. Cocchi F, Devico AL, Garzinodemo A, Cara A, Gallo RC, and Lusso P: The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nature Med 1996;2:1244-1247.
20. Wu LJ, Gerard NP, Wyatt R, Choc H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, and Sodroski J: CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (London) 1996;384:179-183.
21. LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P, Holley LH, Karplus M, Bolognesi DP, Matthews TJ, Emini EA, and Putney SD: Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990;249: 932-935.
22. McCutchan FE, Artenstein AW, Sanders-Buell E, Salminen MO, Carr JK, Mascola JR, Yu X-F, Nelson KE, Khamboonruang C, Schmitt D, Kieny MP, McNeil JG, and Burke DS: Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and Africa. J Virol 1996; 70:3331-3338.
23. Haigwood NL, Shuster JR, Moore GK, Lee H, Skiles PV, Higgins KW, Barr PJ, George NC, and Steimer KS: Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res Hum Retroviruses 1990;6: 855-869.
24. Pialoux G, Excler J-L, Riviere Y, Gonzalez-Canali G, Feuillie V, Coulaud P, Gluckman J-C, Matthews TJ, Meignier B, Kieny MP, Gonnet P, Diaz I, Méric C, Paoletti E, Tartaglia J, Salomon H, Plotkin S, the AGIS Group, and l'Agence National de Recherche sur le SIDA: A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res Hum Retroviruses 1995;11:373-381.
25. Salmon-Céron D, Excler J-L, Sicard D, Blanche P, Finkielstzjen L, Gluckman J-C, Autran B, Matthews TJ, Meignier B, Kieny MP, Valentin C, Gonnet Pi, Diaz I, Salomon H, Pialoux G, Gonzalez-Canali G, Plotkin S, the AGIS Group, and l'Agence Nationale de Recherche sur le SIDA: Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. AIDS Res Hum Retroviruses 1995;11:1479-1486.
26. Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu J-Y, Emini EA, Koenig S, and Zolla-Pazner S: Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol 1992;66:7538-7542.
27. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF III, Burton DR, Ho DD, and Moore JP: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995;69:6609-6617.
28. Excler J-L, Plotkin SA, l'Agence Nationale de Recherche sur le SIDA, the NIAID AVEG Network, and the AGIS Group: HIV vaccination protocols based on priming with poxvirus vectors. In: Retroviruses of Human AIDS and Related Animal Diseases. Dixième Colloque des Cent Gardes, 1995, pp. 279-282.
29. Myagkikh M, Alipanah S, Markham PD, Tartaglia J, Paoletti E, Gallo RC, Franchini G, and Robert-Guroff M: Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res Hum Retroviruses 1996;12:985-992.
30. Montefiori DC, Graham BS, Kliks S, and Wright PF: Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. J Clin Immunol 1992;12: 429-439.
31. Montefiori DC, Graham BS, Zhou J, Zhou J, Bucco RA, Schwartz DH, Cavacini LA, Posner MR, and the NIH-NIAID AIDS Vaccine Clinical Trials Network: V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. J Clin Invest 1993;92:840-847.
32. Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP, Corey L, Stablein DM, Esterlitz JR, Hu S-L, Smith GE, Fast PE, Koff WC, and the National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network: Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J Infect Dis 1993;167:533-537.
33. Graham BS, Gorse GJ, Schwartz DH, Keefer MC, McElrath MJ, Matthews TJ, Wright PF, Belshe RB, Clements ML, Dolin R, and the National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network: Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. J Infect Dis 1994;170:782-786.
34. Langedijk JPM, Back NKT, Durda PJ, Goudsmit J, and Meloen RH: Neutralizing activity of anti-peptide antibodies against the principal neutralization domain of human immunodeficiency virus type 1. J Gen Virol 1991;72:2519-2526.
35. Langedijk JPM, Back NKT, Kinney-Thomas E, Bruck C, Francotte M, Goudsmit J, and Meloen RH: Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1. Arch Virol 1992;126:129-146.
36. Gorny MK, Xu J-Y, Karwowska S, Buchbinder A, and Zolla-Pazner S: Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol 1993;150:635-643.
37. Pincus SH, Messer KG, Schwartz DH, Lewis GK, Graham BS, Blattner WA, and Fisher G: Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J Clin Invest 1993;91:1987-1996.
38. Pincus SH, Messer KG, Nara PL, Blattner WA, Colclough G, and Reitz M: Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. J Clin Invest 1994;93:2505-2513.
39. Pincus SH, Messer KG, Cole R, Ireland R, VanCott TC, Pinter A, Schwartz DH, Graham BS, and Gorse GJ: Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. J Immunol 1997;158:3511-3520.
40. Berman PW, Matthews TJ, Riddle L, Champe M, Hobbs MR, Nakamura GR, Mercer J, Eastman DJ, Lucas C, Langlois AJ, Wurm FM, and Gregory TJ: Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J Virol 1992;66:4464-4469.
41. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Reefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, and Burke DS: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996;173:340-348.
42. Poignard P, Fouts T, Naniche D, Moore JP, and Sattentau QJ: Neutralizing antibodies to human immunodeficiency virus type 1 gp120 induce envelope glycoprotein subunit dissociation. J Exp Med 1996;183:473-484.
43. Pincus SH, Wehrly K, Cole R, Fang H, Lewis GK, McClure J, Conley AJ, Wahren B, Posner MR, Notkins AB, Tilley SA, Pinter A, Eiden L, Teintze M, Dorward D, and Tolstikov VV: In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160. AIDS Res Hum Retroviruses 1996;12:1041-1051.